http://www.medgenics.com/about_us.htm

Medgenics is developing a unique sustained-action therapeutic protein delivery technology for the treatment of a range of chronic diseases. The technology – called a “Biopump” – is made from the patient’s own skin and is implanted in a simple procedure to work inside the patient’s body, to produce and deliver the active protein steadily over a sustained period to treat the targeted disease. Medgenics believes that this biological approach can replace a major portion of the regular and costly injections of therapeutic proteins patients currently receive.

The Company has demonstrated proof-of-principle of its treatment procedure in a clinical trial using EPODURE in anemic patients. A long-acting version of EPODURE designed to produce and deliver a therapeutic dose of EPO steadily for six months or more began Phase I/II efficacy trials in Israel in mid-2008. Clinical trials with INFRADURE are intended follow in due course.

Beyond this, the Company plans to develop a pipeline of products based on its Biopump technology targeting the large and rapidly growing global $50+ billion protein therapy market, which is expected to grow to some $132 billion per year in 2013.

Medgenics is managed by a highly experienced team of biotechnology and biomedical device experts, and its Board of Directors and Scientific Advisory Board include highly experienced figures in the healthcare industry, in healthcare finance, as well as influential figures from the medical community and academia.

Share Price
Medgenics, Inc. commenced trading on the London Stock Exchange Alternative Investment Market (AIM), on Tuesday, 04 December 2007. The stock trades under two symbols: MEDG for Reg S shares and MEDU for unrestricted shares.

Up just under 16%

Medgenics looks to accelerate gene therapy platform after transition year

By Giles Gwinnett

February 20 2014, 2:59pm
The company reported a net loss of US$17.13 million for the year ended December 31 last year compared with a net loss of $15.07 million in 2013


Medgenics (LON:MEDG, NYSE:MDGN) plans to accelerate its gene therapy platform and maximise the potential of its technology assets, it told investors, unveiling 2013 financial results.

The firm is developing Biopump to treat patients and last year repositioned itself as a rare and orphan disease firm with a brand new executive management team.

Michael Cola, president and chief exexcutive, told the statement: "2013 has been an important transition year for us as we build a foundation and corporate strategy to position the company for the future.

He said that based on results to date, the firm had developed a second generation viral vector and Biopump protocol that shows more durable protein production in mice - a model historically predictive of success in human clinical trials.

"We plan to utilise this new vector and protocol as we realign our research and development focus towards the orphan and rare disease market, where we feel the Biopump's attributes of continuous autologous protein/peptide production would be highly advantageous."

Cola said the company had two aims for 2014 - firstly to begin the Phase 1/2 EPODURE trial for human proof-of-concept of the Biopump platform with the second-generation viral vector and protocol, and to replicate the mouse results in humans.

Secondly, the company wants to obtain in-vitro (test tube) and in-vivo (living) preclinical data in human tummy-tuck tissue and mice in several rare and orphan disease indications.

The company reported a net loss of US$17.13 million for the year ended December 31 last year compared with a net loss of $15.07 million in 2012.

Medgenics looks to exit AIM

By Ian Lyall

March 03 2014, 8:07am
The group which is developing a the Biopump for the sustained release of therapeutic proteins.
The group which is developing a the Biopump for the sustained release of therapeutic proteins.


The biotechnology group Medgenics (NYSE MKT:MDGN, LON:MEDG) has unveiled plans to cancel its AIM listing.

The group, which is developing a Biopump for the sustained release of therapeutic proteins, said the high cost of maintaining UK quote as well as limited trading volumes were two of the reasons for the proposed London exit.

Medgenics said it will maintain its quote on the NYSE MKT (formerly the AMEX).

A vote will be heard at the stockholder’s meeting on April 8. If the proposal is approved then the last day of trading on AIM would be April 15.

Medgenics said all stock on the UK share register will be added the US register.

It said either Capita Registrars or Corporate Stock Transfer, the company's US registrar, will send out transmittal letters to all stockholders whose shares were previously UK listed “providing them with further information regarding the transfer of their shares to the company's US share register